VA-INTELSAT
23.3.2022 14:02:14 CET | Business Wire | Press release
Intelsat , operator of the world’s largest integrated satellite and terrestrial network and leading provider of inflight connectivity (IFC), is donating a pioneering piece of satellite history to the Smithsonian’s National Air and Space Museum in Washington, DC. The company will transfer the ground spare of the Intelsat 1 satellite in a ceremony today at the museum’s Steven F Udvar-Hazy Center near Washington Dulles International Airport.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220323005147/en/
Intelsat 1, also known as Early Bird, was the first commercial communications satellite in geosynchronous orbit launched April 6, 1965. During the early age of space technology, two identical satellites were often constructed in the event of launch failure. Today’s donation is a fully constructed satellite that had been on display at Intelsat’s U.S. headquarters.
Through its four years of service, Intelsat 1 played a historic role in connecting humanity. It is credited with broadcasting the Apollo 11 moon landing to millions of TV viewers around the world, doubling the number of telephone lines between the continents, and providing other critical telecommunications and broadcasting services. Intelsat 1 was also the first satellite to provide direct and nearly instantaneous contact between Europe and North America.
“This historic satellite’s new home commemorates its role in some of the most profound moments in human space exploration and global connectivity. Allowing people to witness the moon landing live inspired a generation of space explorers and enthusiasts. This reminder of Intelsat’s integral part in driving humanity forward only underscores how far Intelsat has come today and will continue to go in connecting our world,” said Intelsat CEO Stephen Spengler.
“We are excited to collect the ground spare of the first commercial communications satellite to be placed in geosynchronous orbit,” said Jim David, curator at the National Air and Space Museum. “The Intelsat 1 satellite will be a featured among iconic artifacts like the Hubble space telescope and Skylab in a new exhibition opening in 2025.”
The satellite will be restored and prepared for exhibition at the museum’s Steven F. Udvar-Hazy Center in Chantilly, Virginia. The satellite will eventually be displayed among other spacecraft in a new exhibition, scheduled to open in 2025, as part of the museum’s renovation of its building in Washington, DC.
Intelsat 1 emphasizes Intelsat’s role as the foundational architect of satellite technology – past, present and future. Intelsat's mission is to make broadband more accessible worldwide. With a 50-year record of delivering seamless and secure coverage to government and industry leaders across 200+ countries, the company is investing $2B, initially, to build a unified, global network that will support virtually any access technology, enabling the next generation of global mobility, IoT and 5G services.
To learn more about Early Bird’s history, click here .
For media b-roll, click here .
About Intelsat
As the foundational architects of satellite technology, Intelsat operates the world’s most trusted satellite telecom network. We apply our unparalleled expertise and global scale to connect people, businesses, and communities, no matter how difficult the challenge. Intelsat is building the future of global communications with the world’s first hybrid, multi-orbit, software-defined 5G network designed for simple, seamless, and secure coverage precisely when and where our customers most need it. Follow the leader in global connectivity and “Imagine Here,” with us, at Intelsat.com .
Follow Us on Social Media
:
Twitter
| LinkedIn
| Facebook
| Instagram
| YouTube
View source version on businesswire.com: https://www.businesswire.com/news/home/20220323005147/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
